Hepatitis C Articles (HCV)
Back
	Sofosbuvir+Valpatasvir FDA Approval is expected....       "Gilead filed the NDA for SOF/VEL on October 28, 2015, and FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 28, 2016." http://www.natap.org/2016/HCV/010516_02.htm in phase 3 is ABT-493+ABT-530..... https://clinicaltrials.gov/ct2/show/NCT02604017?term=abt-493&rank=7 in phase 3 is SOF/velpatasvir/GS-9857..... https://clinicaltrials.gov/ct2/show/NCT02607735?term=gs-9857&rank=10 Next coming is Merck's triple regimen.....   EASL:High Efficacy of an 8-Week, 3-Drug Regimen of MK-3682/Grazoprevir/MK-8408 in HCV Genotype 1, 2, or 3-Infected Patients: SVR24 Data from the Phase 2 C-CREST 1 and 2 Studies - (04/19/16)   And J&J's triple regimen............ https://clinicaltrials.gov/ct2/show/NCT02569710?term=al-335&rank=2........J&J HCV Update: AL335+ACH3102+Simeprevir Phase 2 Study - (05/06/16)   Merck's Zepatier was FDA approved early in 2016 and is now available.   EASL: Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study - (04/15/16)   EASL: Sofosbuvir/Velpatasvir for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy - (04/22/16)   Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)   EASL: Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination - (04/21/16)   High Efficacy of Sofosbuvir/Velpatasvir Across 7 HCV Genotypes and 46 Subtypes: Pooled Data From the ASTRAL1, 2 and 3 Trials (12/14/15)   High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials (12/14/15)   Sofosbuvir Plus Velpatasvir (GS-5816) Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15) published   AASLD: Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - (11/30/15)   EASL: Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study - (05/27/16)   EASL: Sofosbuvir / Velpatasvir.... + GS-9857 - (05/05/16)   EASL: Newest HCV Drugs at EASL - (05/05/16)   EASL: ABT-493 + ABT-530 at EASL - (05/05/16)   The International Liver Congress™ EASL - European Association for the Study of the Liver Barcelona, Spain 13-17 April 2016           View Older Articles   Back to Top   www.natap.org